Causalis
Causalis40About
What does Causalis do?
Causalis is focused on addressing the global challenge of chronic condition treatment by developing a robust system to find the optimal balance between treatment efficacy and patient tolerance. Their approach aims to personalize treatment strategies for patients before they start therapy and at critical junctures during treatment.
What is Causalis's revenue?
StartupHub estimates Causalis's annual revenue at $371K (range $226K to $808K, 68% confidence), based on comparable companies in the sector.
When was Causalis founded?
Causalis was founded in 2020.
What industry does Causalis operate in?
Causalis operates in Healthcare, Data, Causal Inference, HealthTech, MedTech, AI-Driven Drug Discovery.
How many employees does Causalis have?
Causalis has approximately 2 people on record.
What is Causalis's current status?
Causalis's current operating status is: Inactive.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
AI-powered platform for personalized weight management and health coaching.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
SYLARIS™ offers premium wearable wellness patches and clinical-grade skincare designed for effortless, intentional, and beautifully designed self-care rituals.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Purpose-built WordPress plugins for healthcare and the agencies that serve them.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 6 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.